Annexon Presents Promising Phase 2 Data for ANX007 in Dry AMD at AAO 2024
Annexon, Inc. (Nasdaq: ANNX) presented new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology (AAO) 2024 meeting. The data demonstrated enhanced protection of vision and greater preservation of central photoreceptor cells in patients with less advanced GA.
Key Highlights:
- Enhanced Vision Protection: Patients with less advanced disease saw greater protection from vision loss, with 0% of patients treated with ANX007 losing 15 letters of vision compared to 17% of sham patients.
- Photoreceptor Protection: ANX007 significantly reduced the loss of photoreceptors in patients with more intact vision at baseline, showing up to a 61% reduction in photoreceptor damage.
- Phase 3 Trial Timeline: Pivotal Phase 3 ARCHER II data are expected in the second half of 2026.
Douglas Love, President and CEO of Annexon commented, “We are further encouraged by ANX007’s more pronounced treatment effect on both preservation of vision and photoreceptors in patients with less advanced disease. Importantly, these Phase 2 data highlight the potential of ANX007 to deliver a differentiated benefit, particularly with earlier intervention in a neurodegenerative disease, and we are encouraged by the promise ANX007 holds to help millions of patients worldwide with dry AMD and GA.”
ANX007 is a first-in-class treatment designed to block C1q locally in the eye, preventing neurodegeneration and preserving vision in dry AMD patients.
